Decoupling Anticancer Efficacy from Cardiac Damage via Stress-Response Inhibition

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Science Translational Medicine https://doi.org/10.1126/scitranslmed.adz7727
Dr. Maria Areli Lorenzana-Carrillo et al.

Points

Investigators identified the protein ZNF281 as a critical transcription factor that triggers heart failure during chemotherapy but paradoxically promotes the rapid growth and metastatic spread of cancerous tumors.
The research team developed a targeted small molecule called ZIM that effectively prevents this protein from binding to DNA, providing total cardiac protection in animal models treated with anthracyclines.
Experimental results showed that mice treated with the new molecule experienced significantly better tumor regression and a complete halt in the spread of cancer to other parts of the body.
Analysis of human heart tissue samples from patients with chemo-induced failure confirmed that the same signaling pathway is active in humans, suggesting high potential for successful clinical translation.
This innovative therapy exploits the different oxygen levels in the heart and tumors to selectively protect healthy cardiac cells while increasing the vulnerability of aggressive cancer cells to treatment.

Summary

This research evaluated the efficacy of a novel small molecule, ZNF281 Interfering Molecule (ZIM), in mitigating chemotherapy-induced cardiotoxicity while simultaneously enhancing anti-tumor activity. The study identified the transcription factor ZNF281 as a central mediator of the heart’s integrated stress response, which is triggered by diverse anticancer agents including anthracyclines, tyrosine kinase inhibitors, and receptor inhibitors. While chronic activation of this pathway induces dilated cardiomyopathy via the upregulation of the enzyme TRIM35, the researchers discovered that ZNF281 conversely promotes cell growth within the hypoxic tumor microenvironment, making it a unique dual-target for cardio-oncology intervention.

Using murine models of lung cancer and melanoma, the investigators demonstrated that ZIM treatment effectively disrupted the binding of ZNF281 to DNA. Mice receiving ZIM alongside doxorubicin exhibited complete protection against cardiac dysfunction and failure, contrasting with the significant ventricular damage observed in control groups. Furthermore, the drug promoted superior tumor regression compared to chemotherapy alone, with several subjects achieving complete regression. The analysis also confirmed that ZIM treatment prevented metastasis, effectively halting the spread of primary tumors to distant organs.

The findings suggest that ZNF281 is a highly translational target, as the protein was found to be significantly induced in myocardial samples from human patients with clinical cardiotoxicity. By exploiting the divergent oxygen-sensing signaling of ZNF281 between the heart and the tumor, ZIM provides a structural foundation for a new class of therapeutics that decouple oncological efficacy from cardiac safety. Future clinical trials are warranted to assess the safety profile of ZIM in humans and its effectiveness across a broader spectrum of malignancies and chemotherapeutic regimens.

Link to the article: https://www.science.org/doi/10.1126/scitranslmed.adz7727

References

Lorenzana-Carrillo, M. A., Tejay, S., Huang, G., Nanoa, J., Zhao, Y.-Y., Wagg, C., Eaton, F., Mendiola Pla, M., Bowles, D. E., Kinnaird, A., Michelakis, E. D., Tabatabaei Dakhili, S. A., Ussher, J. R., & Sutendra, G. (2026). Selective translation of ZNF281 as part of the integrated stress response system has therapeutic relevance for cardio-oncology. Science Translational Medicine, 18(845), eadz7727. https://doi.org/10.1126/scitranslmed.adz7727